Current options in antifungal pharmacotherapy. - Wikidata - wikimedia - TriplyDB

Current options in antifungal pharmacotherapy.

Current options in antifungal pharmacotherapy.

http://www.wikidata.org/entity/Q37151326

about

Progress towards recombinant anti-infective antibodies.Effectiveness of itraconazole on clinical symptoms and radiologic findings in patients with recurrent chronic rhinosinusitis and nasal polyposis Natural products: a continuing source of novel drug leads Elucidating drug resistance in human fungal pathogens.Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.Contribution of galactofuranose to the virulence of the opportunistic pathogen Aspergillus fumigatus Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver functio Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Triazole antifungal agents in invasive fungal infections: a comparative review.Antifungal susceptibility testing: a primer for clinicians.Safety of posaconazole.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Development of antifungal therapies using nanomaterials.Systemic Antifungal Agents: Current Status and Projected Future Developments.PharmGKB summary: voriconazole pathway, pharmacokinetics.Topical and systemic antifungals in dermatology practice.Reversible dilated cardiomyopathy associated with amphotericin B therapy.Immediate cross-hypersensitivity between micafungin and caspofungin: a case report.Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies.Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications An insight into new strategies to combat antifungal drug resistance

P2860

Q33568256-09CBD67D-8FF6-423F-AE1F-FE6A78B58A36 Q34169948-ECA6CF00-062F-4A77-96A2-EA6B64DD6CA2 Q34328933-E2CDD203-5E73-4367-A048-5E34FD0EFF0C Q34419351-2F97D63F-0AE3-408D-BE14-7B3378A62190 Q35715408-53797785-25FB-4D18-BD2C-1EDA20E91CB8 Q36846175-40462FBC-D952-43A4-A3CE-5DA46D6D0521 Q37204164-59915825-3E97-4B17-ACC4-6B4CA3B6B9B3 Q37608276-AF9AF5B9-3220-4713-8163-3BC4A06B2678 Q37776005-467D2362-DDD4-4D34-B375-ECD659D286E6 Q37918556-E170F2A3-569F-4BB5-AEBA-DD1FD3958116 Q37964703-E6122608-756D-4E81-B950-D3AAC8CD64DD Q38061087-3F6F8B41-727F-4BE9-AAE9-8E31994D0CAE Q38077591-6BA05799-37F7-4BD3-883E-37EF51EE5849 Q38140015-E47FE697-9DBA-46D8-99DB-AE99BFD23C48 Q38222570-259875B1-FB17-466F-AA3B-83C172D6A328 Q38285488-784F4395-AA00-40D0-914E-FCCA9623BDD8 Q38658275-A9710ED9-9C76-4962-8861-1E8CDD5E7DE4 Q38796140-69E9A9BA-5BB2-4CB1-B703-49BDFFC31127 Q38918175-C8123B5B-FA45-4A15-941C-1482E6E0E47A Q40442939-35DC4201-6A39-4E12-BB9E-A0142B14B4B9 Q41610197-55863113-91A1-4C0A-AE02-9758D115196B Q46093154-D1E5D84F-D789-4CEF-804A-AB075BB379C5 Q47882912-DFB69097-DF1B-496A-992A-9D12CD1B9715 Q56993256-976986A9-2CDE-4C4E-9A13-0ABFFD1FEDAA Q59135042-2365D00D-2481-4709-ADDC-4D045B0F9A1F

P2860

Current options in antifungal pharmacotherapy.

http://www.wikidata.org/entity/Q37151326

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Current options in antifungal pharmacotherapy.

@en

Current options in antifungal pharmacotherapy.

@nl

type

label

Current options in antifungal pharmacotherapy.

@en

Current options in antifungal pharmacotherapy.

@nl

prefLabel

Current options in antifungal pharmacotherapy.

@en

Current options in antifungal pharmacotherapy.

@nl

P1433

Q37151326-8A6DA5F2-CDA9-456E-911C-81ABFAE675EE

P1476

Q37151326-34C71FD8-7F98-4F5A-981E-E7EBF2A99F6B

P2093

Q37151326-08096C4A-B0E4-463E-939B-062403714C0E

Q37151326-5D59B371-2242-43A2-B271-701EEBEA4E58

Q37151326-BA266346-87B6-4BCA-909F-ECBCD757CC8F

Q37151326-E699D537-145D-48C9-B71A-1F8E46F420E5

P2860

Q37151326-034F258A-439C-46DB-8110-38187857A10E

Q37151326-05078688-DE08-4A02-B9B9-9626C966F252

Q37151326-0632A6A0-B04F-4B7B-9D32-88161112D84F

Q37151326-0638DCB3-A2E1-4341-9F08-F99F1C3EB4F8

Q37151326-08990261-999C-476F-9FC2-792C4C8FE620

Q37151326-0905AE15-072F-436D-8690-AE564D0A58FB

Q37151326-0D9D8E01-4777-4A34-B597-A8CB309E4473

Q37151326-0DE57EDA-4D79-46F1-898B-C0A1A33A63C5

Q37151326-0EBF1B33-FC4C-4CA9-8F9D-073B5F2E5098

Q37151326-0EF26775-597D-4B9A-9017-AC3C92D19BDF

P304

Q37151326-A3B361A6-3B95-4525-90A3-665BF505FF20

P31

Q37151326-2B9CC135-D9AD-4B89-AF28-DA1C0C8AEF14

P356

Q37151326-A08CAC8F-6580-4F42-BDF5-9783807F0BBD

P407

Q37151326-ED938AC5-1AB5-4A77-A68D-F4799CF0A706

P433

Q37151326-22C06A69-78F0-4B51-A55F-5455CC338380

P478

Q37151326-07413427-ABD4-4012-9623-64904A554E3B

P50

Q37151326-6EB1A90E-62D9-4B62-8407-493CA50A312C

P577

Q37151326-B2F3E94A-5F29-4B83-865E-1ADAD8D36ADF

P698

Q37151326-BE715F2C-B555-4769-9343-346496A2BD19

P921

Q37151326-388BAA0B-B9D5-4783-A533-48FD0A7D833F

P356

P1433

Pharmacotherapy

P1476

Current options in antifungal pharmacotherapy

@en

P2093

James S Lewis

http://www.w3.org/2001/XMLSchema#string

John Mohr

http://www.w3.org/2001/XMLSchema#string

Luis Ostrosky-Zeichner

http://www.w3.org/2001/XMLSchema#string

Travis Cooper

http://www.w3.org/2001/XMLSchema#string

P2860

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-gamma

The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase.

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

Echinocandins: a new class of antifungal

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

P304

614-645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.28.5.614

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Melissa D. Johnson

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18447660

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy